Clinical Trial

Home/Tag: Clinical Trial

A ‘Clinical Trial of One’

October's LRG newsletter features artist Douglas Morgan, who found himself with a rare GIST mutation and no treatment options until an innovative oncologist and a compassionate gesture by a pharmaceutical company gave him a chance to receive a unique treatment.

By |2019-11-08T11:08:49-05:00October 29th, 2019|Clinical Trials, Member Stories, News, Newsletter|

Deciphera Releases Positive Trial Results for Ripretinib

Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]

By |2019-08-14T09:38:14-04:00August 14th, 2019|Drug Treatment, News, Research|

Life Fest 2 Pharma Panel: Addressing Key Mechanisms of Tumor Drug Resistance

Pharma Panel: Overview of Promising Trials for GIST "Addressing Key Mechanisms of Tumor Drug Resistance" Deciphera Pharmaceuticals view all Life Fest 2018 Videos

By |2019-03-20T09:37:21-04:00September 18th, 2018|Clinical Trials, Events, Video|

It’s a Journey: Our Experience on Clinical Trials

By Jennifer Moore, LRG Member I was waiting in line to pick up a new prescription for Gleevec when my husband ran in and told me to forget it. After two surgeries, a year [...]

By |2020-01-31T10:44:52-05:00December 28th, 2017|Clinical Trials, Member Stories, News, Newsletter|

New Data Indicates Imatinib Boosts Long-Term Survival for Some GIST Patients

A significant finding from a newly published study in JAMA Oncology, indicates that nearly one-fourth of GIST patients with advanced disease initially treated with imatinib will survive for ten years or more. The study, [...]

By |2018-10-30T09:19:32-04:00February 27th, 2017|News, Research|

Study Indicates Use Of Adjuvant Imatinib Therapy For GIST Increasing

A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]

By |2018-09-11T09:21:47-04:00April 7th, 2015|Drug Treatment, Gleevec, News, Survival Strategies|

Novartis Gains Approval for Panobinostat

Novartis Pharmaceuticals recently received FDA approval for panobinostat, a blood cancer drug that targets multiple myeloma. This was a surprising ruling, as it was a turnaround from last year’s Oncologic Drugs Advisory Committee’s 5-2 [...]

By |2019-04-08T09:34:28-04:00March 9th, 2015|Clinical Trials, Drug Treatment, News|
Go to Top